Peter’s scientific background lies in the field of condensed matter physics, biophysics, and bioinformatics. He was top-2 cited Russian physicist under 35 and has conducted research at Kurchatov Institute, one of the leading science government agencies in Russia, AMOLF, a national research center in the Netherlands, and the University of Innsbruck. Peter studied theoretical physics in the Moscow Institute of Physics and Technology and obtained his Ph.D. from the University of Amsterdam and currently has over 70 publications in peer-reviewed journals and multiple patents. As an MIPT researcher and a head of the Biological Systems Simulation Lab, he is working on modeling complex biological systems with the help of methods borrowed from statistical physics, kinetics and physical dynamics. As a biotech entrepreneur, he led the projects in research and pre-clinical development of anti-inflammatory, anti-infectious and anti-aging compounds, technology licensing and drug discovery collaborations with pharma (including members of World Top 20) and Academia.
Peter is a founder and CEO of Gero LLC,
Gero is an AI driven drug discovery company using big human medical data for identification of innovative therapeutics (Approach is described in https://www.frontiersin.org/articles/10.3389/fgene.2018.00483/full). Gero’s flagship project is a pipeline pipeline of longevity therapeutics. Recent results include experimental therapies rejuvenating / reducing biological age and frailty in mice. Gero works with leading academic partners , including Brian Kennedy, Aubrey de Grey, Robert J. Shmookler Reis, Vadim Gladyshev, Yuri Aulchenko, Andrei Gudkov and others to translate aging biology into life-changing interventions against biological aging acceleration in cancer, metabolic disorders and immunosenescence.